protoporphyrin ix has been researched along with Psoriasis in 14 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis." | 9.12 | A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. ( Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "Protoporphyrin IX-induced red fluorescence can be used as a novel and convenient approach for psoriasis diagnosis and progression evaluation." | 7.85 | Protoporphyrin IX fluorescence as potential indicator of psoriasis severity and progression. ( Sroka, R; Wang, B; Wang, HW; Wang, XL; Xu, YT; Zhang, L; Zheng, J, 2017) |
| "Psoriasis lesions accumulate protoporphyrin IX (PpIX) with a variable distribution within plaques due to variations in hyperkeratosis causing differences in penetration of cream or light." | 7.76 | The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. ( Gerritsen, RM; Kanis, JH; Kleinpenning, MM; Smits, T; van de Kerkhof, P; van Erp, PE, 2010) |
| " This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm." | 7.69 | The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. ( Collins, P; Robinson, DJ; Sheehan-Dare, RA; Stables, GI; Stringer, MR, 1996) |
| "To study the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis." | 5.12 | A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. ( Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "Protoporphyrin IX-induced red fluorescence can be used as a novel and convenient approach for psoriasis diagnosis and progression evaluation." | 3.85 | Protoporphyrin IX fluorescence as potential indicator of psoriasis severity and progression. ( Sroka, R; Wang, B; Wang, HW; Wang, XL; Xu, YT; Zhang, L; Zheng, J, 2017) |
| "Psoriasis lesions accumulate protoporphyrin IX (PpIX) with a variable distribution within plaques due to variations in hyperkeratosis causing differences in penetration of cream or light." | 3.76 | The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis. ( Gerritsen, RM; Kanis, JH; Kleinpenning, MM; Smits, T; van de Kerkhof, P; van Erp, PE, 2010) |
| "Psoriasis has been shown to highly accumulate protoporphyrin IX (PpIX), but a variable distribution within plaques after fluorescence diagnosis is seen." | 3.73 | Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. ( Ewalds, E; Gerritsen, MJ; Kleinpenning, MM; Smits, T; van de Kerkhof, PC; van Erp, PE, 2006) |
| "Increased endogenous levels of protoporphyrin IX (PpIX) have been reported in the skin of patients with psoriasis." | 3.72 | Repeated exposure to blue light does not improve psoriasis. ( Bissonnette, R; Maari, C; Viau, G, 2003) |
| "Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) has been shown in previous studies to improve psoriasis." | 3.71 | Oral aminolevulinic acid induces protoporphyrin IX fluorescence in psoriatic plaques and peripheral blood cells. ( Bissonnette, R; Korbelik, M; Lui, H; McLean, DI; Zeng, H, 2001) |
| " This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm." | 3.69 | The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. ( Collins, P; Robinson, DJ; Sheehan-Dare, RA; Stables, GI; Stringer, MR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, B | 1 |
| Xu, YT | 1 |
| Zhang, L | 1 |
| Zheng, J | 1 |
| Sroka, R | 1 |
| Wang, HW | 1 |
| Wang, XL | 1 |
| Wen, X | 1 |
| Li, Y | 1 |
| Hamblin, MR | 1 |
| Smits, T | 5 |
| van Laarhoven, AI | 1 |
| Staassen, A | 1 |
| van de Kerkhof, PC | 4 |
| van Erp, PE | 5 |
| Gerritsen, MJ | 4 |
| Fang, YP | 1 |
| Huang, YB | 1 |
| Wu, PC | 1 |
| Tsai, YH | 1 |
| Kleinpenning, MM | 3 |
| Kanis, JH | 1 |
| van de Kerkhof, P | 1 |
| Gerritsen, RM | 1 |
| Bissonnette, R | 4 |
| Tremblay, JF | 1 |
| Juzenas, P | 1 |
| Boushira, M | 1 |
| Lui, H | 3 |
| Maari, C | 1 |
| Viau, G | 1 |
| Robles, CA | 1 |
| Ewalds, E | 1 |
| Stringer, MR | 2 |
| Collins, P | 2 |
| Robinson, DJ | 2 |
| Stables, GI | 2 |
| Sheehan-Dare, RA | 2 |
| Zeng, H | 2 |
| McLean, DI | 2 |
| Schreiber, WE | 1 |
| Roscoe, DL | 1 |
| Korbelik, M | 1 |
1 review available for protoporphyrin ix and Psoriasis
| Article | Year |
|---|---|
Photodynamic therapy in dermatology beyond non-melanoma cancer: An update.
Topics: Acne Vulgaris; Aminolevulinic Acid; Collagen; Humans; Photochemotherapy; Photosensitizing Agents; Po | 2017 |
3 trials available for protoporphyrin ix and Psoriasis
| Article | Year |
|---|---|
Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.
Topics: Administration, Oral; Aminolevulinic Acid; Apoptosis; CD3 Complex; Epidermis; Erythema; Humans; Phot | 2002 |
A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis.
Topics: Adult; Aminolevulinic Acid; Cell Differentiation; Cell Proliferation; Dose Fractionation, Radiation; | 2006 |
The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Chronic Disease; Dose-Response Relationship, Radiation; Humans; Photochemothera | 1997 |
10 other studies available for protoporphyrin ix and Psoriasis
| Article | Year |
|---|---|
Protoporphyrin IX fluorescence as potential indicator of psoriasis severity and progression.
Topics: Disease Progression; Female; Fluorescence; Humans; Male; Photochemotherapy; Photosensitizing Agents; | 2017 |
Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photose | 2009 |
Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Chemistry, Pharmaceutical; Disease Models, | 2009 |
The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Analysis of Variance; Bandages, Hydrocolloid; Bi | 2010 |
Repeated exposure to blue light does not improve psoriasis.
Topics: Adult; Aged; Humans; Middle Aged; Protoporphyrins; Psoriasis; Skin | 2003 |
Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid.
Topics: Aminolevulinic Acid; DNA; Humans; Keratosis; Protoporphyrins; Psoriasis; Spectrometry, Fluorescence | 2005 |
Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Biopsy; Cell Differentiation; Cell Proliferati | 2006 |
The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy.
Topics: Administration, Topical; Aminolevulinic Acid; Dose-Response Relationship, Drug; Humans; Photochemoth | 1996 |
Psoriatic plaques exhibit red autofluorescence that is due to protoporphyrin IX.
Topics: Fluorescence; Humans; Photosensitizing Agents; Protoporphyrins; Psoriasis; Skin; Spectrometry, Fluor | 1998 |
Oral aminolevulinic acid induces protoporphyrin IX fluorescence in psoriatic plaques and peripheral blood cells.
Topics: Administration, Oral; Aminolevulinic Acid; Blood Cells; Fluorescence; Humans; Photochemotherapy; Pho | 2001 |